ss-31 dosage: Frequently asked questions

Discard it immediately. A single temperature excursion to room temperature (20-25°C) for 8-12 hours causes partial peptide aggregation and oxidation of methionine residues critical to the cardiolipin-binding mechanism. The solution may still appear clear, but potency drops by 40-60%. You're injecting degraded protein fragments, not functional peptide. Mitochondrial membrane stabilisation requires intact peptide structure, and there's no home test to verify structural integrity after temperature abuse.

Measurable improvements in six-minute walk distance and NT-proBNP levels appeared within two weeks of daily 0.25 mg/kg dosing in the HFpEF trial, with maximum benefit observed at four weeks. The delayed onset reflects cumulative cardiolipin stabilization rather than acute receptor activation. Mitochondrial cristae remodeling takes time. If no improvement appears by week three, consider whether the underlying pathology is driven by mitochondrial dysfunction (SS-31 responsive) or inflammation and fibrosis (SS-31 non-responsive).

Calculate injection volume as 1.2mg ÷ 2.5mg/mL = 0.48mL. Insulin syringes are typically graduated in 0.01mL increments, so you can accurately draw 0.48mL by aligning the plunger with the midpoint between the 0.47mL and 0.49mL marks. If your syringe only has 0.1mL graduations, the closest measurable volume is 0.5mL, which delivers 1.25mg. A 4% overshoot.

Recalculate immediately using the verified purity before reconstituting. A 5mg vial at 94% purity contains 4.7mg active peptide, not 4.9mg. If you proceed assuming 98%, every dose will be 4% weaker than intended. Adjust your target concentration or reconstitution volume to compensate: either use less solvent to maintain the same mg/mL concentration, or accept a slightly lower concentration and increase injection volume accordingly.

This indicates the lyophilised powder had residual moisture or the vacuum seal was compromised during shipping. The visible liquid volume may be 2.1–2.3mL when you added exactly 2.0mL of bacteriostatic water. Do not use the higher observed volume in your concentration formula. Calculate using only the volume you added (2.0mL). If the excess is more than 0.2mL above your added volume, the vial may have been compromised; contact the supplier for replacement.

Start with 2.0 mg/kg daily administered subcutaneously for at least 28 days and measure functional endpoints (ejection fraction, exercise tolerance, biomarkers like NT-proBNP) before deciding whether to escalate. Chronic models require time for mitochondrial remodeling. Improvements in ATP production efficiency and reduced ROS generation accumulate over weeks, not hours. If baseline dysfunction is severe (as in Barth syndrome or advanced heart failure), escalation to 4.0 mg/kg is justified, but doses above 4.0 mg/kg should be reserved for models with near-complete cardiolipin depletion where binding site saturation is genuinely unattainable at lower doses.

Use 3–5mg/kg IV bolus administered 30–60 minutes before anticipated ischemia. The mechanism requires SS-31 presence in mitochondria before ATP depletion triggers cristae remodelling. Post-injury dosing reduces efficacy by 50% or more. If the injury timing is unpredictable, switch to twice-daily SC dosing at 1–2mg/kg to maintain baseline protection.

Discard it immediately. Do not inject. Cloudiness indicates protein aggregation or microbial contamination, both of which render the peptide inactive or unsafe. SS-31 in proper solution is clear and colourless; any deviation signals structural breakdown. The most common cause is incorrect reconstitution (injecting water directly onto the powder rather than down the vial wall) or a compromised sterile seal.

Mild redness or slight swelling at the injection site within 2–6 hours is common and typically resolves within 24 hours. Rotate injection sites (abdomen, thigh, upper arm) to prevent repeated irritation. Persistent reactions beyond 48 hours or signs of infection (heat, spreading redness, pus) require immediate medical evaluation and suggest either contamination or an allergic response to the carrier solution.

Increase to 0.35mg/kg and reassess at week four. Healthy mitochondria require higher circulating SS-31 concentrations to saturate cardiolipin binding sites compared to dysfunctional mitochondria, which have reduced cristae density and fewer binding targets. Subjective energy changes lag behind ATP synthesis improvements by 10–14 days because you're feeling the downstream effects (improved NAD+ recycling, reduced lactate accumulation) rather than the direct mitochondrial mechanism. If no change persists at 0.35mg/kg by week six, verify storage conditions and reconstitution technique. Degraded peptide is the most common cause of non-response in correctly dosed protocols.

Skeletal muscle, liver, and adipose tissue contain 60–80% less cardiolipin than cardiac or renal tissue. Lower your dose to 0.5–1mg/kg and increase frequency rather than raising total amount. Excess peptide won't bind and simply clears through renal excretion. Functional outcomes in low-cardiolipin tissues require 4+ weeks of consistent dosing because the effect accumulates through reduced chronic oxidative damage, not acute rescue.

Start at 0.3mg/kg and track subjective markers: resting heart rate upon waking, post-meal energy dips, recovery time after high-intensity exercise, and cognitive clarity during fasted morning hours. If you notice measurable improvement within two weeks, your baseline function was likely suboptimal and you've hit effective threshold. If no change by week four, increase to 0.4mg/kg. Formal mitochondrial testing (muscle biopsy for electron transport chain enzyme activity, or organic acid testing for Krebs cycle intermediates) provides objective data but isn't required for energy-focused protocols. Response to titration reveals your functional status indirectly.

Administer the missed dose as soon as you remember if fewer than 4 days have passed, then return to your regular schedule. If more than 4 days have passed, skip the missed dose and resume on your next scheduled injection date. Do not double-dose. Missing a single week in a 12-week protocol has minimal impact on cumulative mitochondrial outcomes based on extended primate studies.

Reduce injection volume by preparing SS-31 at higher concentration (10mg/mL instead of 5mg/mL), and rotate injection sites across abdomen, thighs, and upper arms. Burning typically indicates high peptide concentration in a localised subcutaneous pocket. Spreading the dose across two smaller injections (morning and evening) at the same total daily dose often resolves this without requiring dose reduction. Persistent redness beyond 24 hours or expanding welts suggest immune response to the benzyl alcohol in bacteriostatic water; switch to sterile water for injection, though this reduces storage life to 72 hours refrigerated.

Verify mitochondrial uptake and tissue distribution before escalating the dose. SS-31 accumulation in cardiac mitochondria can be measured directly using mass spectrometry or indirectly by assessing ATP production and ROS levels in isolated mitochondria. If uptake is confirmed but outcomes are unchanged, the issue is likely mechanistic mismatch (the injury model doesn't involve cardiolipin-mediated dysfunction) rather than insufficient dosing. Escalating dose when the mechanism isn't engaged wastes resources. Pivot to confirming that cardiolipin oxidation is actually occurring in your model before assuming more peptide will solve the problem.

Use 0.5 mg/kg administered as a bolus or 4-hour infusion starting immediately before or during reperfusion. The mechanism depends on SS-31 being present during the oxidative burst that occurs when blood flow is restored to ischemic tissue. Delayed administration significantly reduces efficacy. Doses above 1.0 mg/kg have not demonstrated superior infarct reduction in published models, so escalation beyond this point wastes compound. If your model includes reperfusion injury lasting more than 4 hours, consider divided dosing (0.5 mg/kg at reperfusion onset, then 0.25 mg/kg at 2 hours and 4 hours) to maintain plasma levels throughout the critical oxidative window.

SS-31 binds cardiolipin reversibly without redox activity. It's a structural stabiliser, not an antioxidant. MitoQ and SkQ1 deliver CoQ10 or plastoquinone to mitochondria and work through direct ROS scavenging. SS-31 outperforms lipophilic antioxidants in models where cristae structure collapse drives pathology (Barth syndrome, ischemia-reperfusion), while MitoQ shows stronger effects in models driven purely by oxidative damage without structural defects. Don't assume they're interchangeable. The mechanisms target different steps in mitochondrial failure.

Multiply the micromolar concentration by SS-31's molecular weight (639.8 g/mol) and convert units systematically. A published protocol stating '100μM tissue concentration' doesn't directly translate to mg/kg dosing without knowing tissue volume and distribution kinetics, but when literature reports administered doses as μmol/kg, the conversion is: mg/kg = (μmol/kg × 639.8) / 1000. A 0.39μmol/kg dose equals 0.25mg/kg. Some neurological research papers report cerebrospinal fluid concentrations in nanomolar ranges (10–50nM achieved therapeutic effects in one published model)—these reflect tissue measurements, not administered doses, and cannot be back-calculated to dosing protocols without pharmacokinetic modeling.

Recalculate injection volume immediately using the actual concentration rather than assumed values. If you reconstituted 15mg powder with 3mL bacteriostatic water but the concentration measures differently (verified via spectrophotometry or HPLC if available), adjust your volume-to-dose calculations accordingly—drawing incorrect volumes based on assumed concentration is the most common dosing error in peptide research. For a target 0.25mg/kg dose in a 70kg subject (17.5mg total), a 4mg/mL solution requires 4.375mL injection volume while a 6mg/mL solution requires only 2.92mL. The equation Volume = Target Dose (mg) / Measured Concentration (mg/mL) must use verified concentration values, not package label claims, because reconstitution technique and peptide purity affect final concentration.

Apply allometric scaling equations rather than direct weight conversion to calculate SS-31 dosage across species. The FDA-recognized allometric scaling method accounts for metabolic rate differences: HED (mg/kg) = Animal Dose (mg/kg) × (Animal Km / Human Km), where Km values are mouse = 3, rat = 6, dog = 20, human = 37. A mouse protocol using 1.0mg/kg translates to 0.08mg/kg human-equivalent dose, not 1.0mg/kg. This explains why preclinical cardiac models commonly use 0.4–0.5mg/kg in rodents while clinical trials start at 0.05–0.06mg/kg in humans—the doses are equivalent after allometric adjustment. Direct weight-based scaling systematically overestimates appropriate doses in larger species and ignores pharmacokinetic differences in clearance rates.